{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:34:56Z","timestamp":1789623296932,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00198-016-3503-0","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T10:14:29Z","timestamp":1455531269000},"page":"2099-2107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Continuous treatment with odanacatib for up to 8\u00a0years in postmenopausal women with low bone mineral density: a phase 2 study"],"prefix":"10.1007","volume":"27","author":[{"given":"R.","family":"Rizzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-L.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Halse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Rodr\u00edguez Portales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Verbruggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"3503_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel","year":"2001","unstructured":"NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"3503_CR2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276\u20131287","journal-title":"Lancet"},{"key":"3503_CR3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"3503_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23\u201357","journal-title":"Osteoporos Int"},{"key":"3503_CR5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s00198-014-2755-9","volume":"25","author":"R Rizzoli","year":"2014","unstructured":"Rizzoli R, Branco J, Brandi ML et al (2014) Management of osteoporosis of the oldest old. Osteoporos Int 25:2507\u20132529","journal-title":"Osteoporos Int"},{"key":"3503_CR6","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis\u2014where do we go from here? N Engl J Med 366:2048\u20132051","journal-title":"N Engl J Med"},{"key":"3503_CR7","unstructured":"Eli Lilly and Company (2012) FORTEO prescribing information. www.forteo.com . Accessed 26 Jan 2016"},{"key":"3503_CR8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","volume":"18","author":"JY Gauthier","year":"2008","unstructured":"Gauthier JY, Chauret N, Cromlish W et al (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923\u2013928","journal-title":"Bioorg Med Chem Lett"},{"key":"3503_CR9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jbmr.1477","volume":"27","author":"T Cusick","year":"2012","unstructured":"Cusick T, Chen CM, Pennypacker BL et al (2012) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27:524\u2013537","journal-title":"J Bone Miner Res"},{"key":"3503_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jbmr.1475","volume":"27","author":"PJ Masarachia","year":"2012","unstructured":"Masarachia PJ, Pennypacker BL, Pickarski M et al (2012) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27:509\u2013523","journal-title":"J Bone Miner Res"},{"key":"3503_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","volume":"86","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Zajic S, Stone J et al (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 86:175\u2013182","journal-title":"Clin Pharmacol Ther"},{"key":"3503_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","volume":"25","author":"HG Bone","year":"2010","unstructured":"Bone HG, McClung MR, Roux C et al (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937\u2013947","journal-title":"J Bone Miner Res"},{"key":"3503_CR13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ et al (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242\u2013251","journal-title":"J Bone Miner Res"},{"key":"3503_CR14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"B Langdahl","year":"2012","unstructured":"Langdahl B, Binkley N, Bone H et al (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 27:2251\u20132258","journal-title":"J Bone Miner Res"},{"key":"3503_CR15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S8756-3282(00)00235-0","volume":"26","author":"ML Sassi","year":"2000","unstructured":"Sassi ML, Eriksen H, Risteli L et al (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367\u2013373","journal-title":"Bone"},{"key":"3503_CR16","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2010.11.033","volume":"66","author":"TM R\u00fcnger","year":"2012","unstructured":"R\u00fcnger TM, Adami S, Benhamou CL et al (2012) Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 66:e89\u2013e96","journal-title":"J Am Acad Dermatol"},{"key":"3503_CR17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaad.2008.03.009","volume":"59","author":"A Peroni","year":"2008","unstructured":"Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G (2008) Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 59:125\u2013129","journal-title":"J Am Acad Dermatol"},{"key":"3503_CR18","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00198-014-2719-0","volume":"25","author":"CE Kawalilak","year":"2014","unstructured":"Kawalilak CE, Johnston JD, Olszynski WP, Kontulainen SA (2014) Characterizing microarchitectural changes at the distal radius and tibia in postmenopausal women using HR-pQCT. Osteoporos Int 25:2057\u20132066","journal-title":"Osteoporos Int"},{"key":"3503_CR19","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, Delmas PD, Hanley DA et al (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886\u20131894","journal-title":"J Bone Miner Res"},{"key":"3503_CR20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831","journal-title":"N Engl J Med"},{"key":"3503_CR21","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jbmr.2194","volume":"29","author":"AM Cheung","year":"2014","unstructured":"Cheung AM, Majumbdar S, Brixen K et al (2014) Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength. J Bone Miner Res 29:1786\u20131794","journal-title":"J Bone Miner Res"},{"key":"3503_CR22","doi-asserted-by":"crossref","unstructured":"Pennypacker BL, Gilberto D, Gatto NT et al (2016) Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model. J Orthop Res 34:72\u201380","DOI":"10.1002\/jor.22982"},{"key":"3503_CR23","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/jbmr.2211","volume":"29","author":"BL Pennypacker","year":"2014","unstructured":"Pennypacker BL, Chen CM, Zheng H et al (2014) Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J Bone Miner Res 29:1847\u20131858","journal-title":"J Bone Miner Res"},{"key":"3503_CR24","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky MS, Libanati C, Niu QT et al (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30:1280\u20131289","journal-title":"J Bone Miner Res"},{"key":"3503_CR25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1210\/jc.2012-2972","volume":"98","author":"K Brixen","year":"2013","unstructured":"Brixen K, Chapurlat R, Cheung AM et al (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571\u2013580","journal-title":"J Clin Endocrinol Metab"},{"key":"3503_CR26","first-page":"499","volume":"52","author":"JM Halleen","year":"2006","unstructured":"Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK (2006) Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52:499\u2013509","journal-title":"Clin Lab"},{"key":"3503_CR27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bone.2008.08.130","volume":"44","author":"B Pennypacker","year":"2009","unstructured":"Pennypacker B, Shea M, Liu Q et al (2009) Bone density, strength, and formation in adult cathepsin K (\u2212\/\u2212) mice. Bone 44:199\u2013207","journal-title":"Bone"},{"key":"3503_CR28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692","journal-title":"Bone"},{"key":"3503_CR29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00223-013-9800-0","volume":"94","author":"PR Jensen","year":"2014","unstructured":"Jensen PR, Andersen TL, Pennypacker BL, le Duong T, Delaiss\u00e9 JM (2014) The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits. Calcif Tissue Int 94:212\u2013222","journal-title":"Calcif Tissue Int"},{"key":"3503_CR30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-014-0196-1","volume":"12","author":"NA Sims","year":"2014","unstructured":"Sims NA, Ng KW (2014) Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep 12:98\u2013106","journal-title":"Curr Osteoporos Rep"},{"key":"3503_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","volume":"126","author":"M McClung","year":"2013","unstructured":"McClung M, Harris ST, Miller PD et al (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126:13\u201320","journal-title":"Am J Med"},{"key":"3503_CR32","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1345\/aph.1Q543","volume":"46","author":"EE Sutton","year":"2012","unstructured":"Sutton EE, Riche DM (2012) Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 46:1000\u20131009","journal-title":"Ann Pharmacother"},{"key":"3503_CR33","unstructured":"McClung MR, Langdahl B, Papapoulos S et al (2015) Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III Long-Term Odanacatib Fracture Trial (LOFT). IBMS BoneKEy 13:Article number:677. Abstract OC4.4"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3503-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-016-3503-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3503-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T10:52:49Z","timestamp":1718362369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-016-3503-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3503"],"URL":"https:\/\/doi.org\/10.1007\/s00198-016-3503-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]}}}